China’s vaccine specialist CanSino Biologics Inc. has secured a Beijing patent approval for its COVID-19 vaccine candidate Ad5-nCOV, announced by state media, citing documents from the country’s intellectual property regulatory authority.
It is China’s first COVID-19 vaccine patent, the state-owned People’s Daily newspaper reported on Sunday. The paper quoted documents released by the National Intellectual Property Administration of China stating the patent was granted on 11 August.
Saudi Arabia has stated that it plans to start phase III clinical trials of the CanSino vaccine this month. CanSino said that it is also in talks with Russia, Brazil and Chile to launch phase III trials in those countries. CanSino’s Hong Kong shares rose by approximately 14 per cent in the morning session on Monday. Its shares in Shanghai rose by 6.6 per cent as of midday.